Limoges, France 360° Virtual Tour
In this 360° Virtual Tour of our Limoges, France site, explore Catalent’s European center of excellence for early-phase clinical biologics formulation development and drug product fill/finish.
Beinheim, France 360° Virtual Tour
In this 360° virtual tour, explore Catalent’s Beinheim, France facility which houses Rx and OTC softgel development and manufacturing operations. This site specializes in formulation development and manufacturing solutions of controlled substances, highly potent compounds, and hormones.
Gosselies, Belgium Site Tour Video
Catalent has a network of Cell Therapy clinical and commercial manufacturing facilities in the US and Europe. Discover our capabilities for the development and manufacturing of allogeneic and autologous immuno- and stem-cell therapies. Learn about our expertise in both early and late-stage manufacturing as you get a glimpse inside our cell therapy facility in Gosselies.
Eberbach, Germany 360° Virtual Tour
In this 360° Virtual Tour, explore our biggest European softgel development and manufacturing facility in Eberbach, Germany. With capacity of 12.8 billion softgel capsules per year, it features integrated softgel manufacturing services including coating and packaging simplify supply chain management and deliver products faster to market. The facility can handle highly potent and cytotoxic compounds with our self-contained, separated cytotoxic suite.
Clinical Supply – Schorndorf, Germany Site Tour Video
In this video, tour the Catalent Clinical Supply Services facility in Schorndorf, Germany, and explore our innovative and flexible end-to-end clinical supply solutions for Europe and beyond, including packaging, labeling, and storage and distribution services for your oral, biologic, and advanced therapy medicinal products.
Swindon, UK Site Tour Video
Catalent’s Swindon, UK facility, located 85 miles west of central London, is the manufacturing center for Catalent’s Zydis® Orally Disintegrating Tablet (ODT) platform. Equipped with high-speed manufacturing suites, the site produces approximately 1.2B doses per year and supports both Rx and OTC products as well as potent and controlled substances.